Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04871542 · ClinicalTrials.gov registry record
Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
A clinical trial of Malignant Solid Neoplasm, sponsored by SWOG Cancer Research Network.
- Recruiting
- Registry status
- 2,062
- Enrollment target
- 6
- Study locations
NCT04871542: Recruiting study of Malignant Solid Neoplasm, sponsored by SWOG Cancer Research Network.
NCT04871542 is a study of Malignant Solid Neoplasm that is actively recruiting participants, run by SWOG Cancer Research Network. The registered enrollment target is 2,062 participants, above the 1,129-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (83% higher). The trial reports 6 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04871542, a study of Malignant Solid Neoplasm, is actively recruiting participants, sponsored by SWOG Cancer Research Network.
- RECRUITING
- Registry status
- 2,062 participants
- Enrollment target
- 6
- Study locations
Study Summary
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Primary Outcome
Adverse events will be recorded according to the physician rated Common Terminology Criteria for Adverse Events (CTCAE) scoring system.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- OTHER Questionnaire Administration
Study Locations (6)
Iowa
- Mary Greeley Medical Center - Ames
- McFarland Clinic PC - Ames - Ames
- McFarland Clinic PC-Boone - Boone
- McFarland Clinic PC-Trinity Cancer Center - Fort Dodge
- McFarland Clinic PC-Jefferson - Jefferson
- McFarland Clinic PC-Marshalltown - Marshalltown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,062 participants |
| Start Date | 2021-09-13 |
| Est. Completion | 2028-03-14 |
What NCT04871542 shows while recruiting
NCT04871542 is an observational study that tracks outcomes without assigning an intervention. Its 2,062 participants enrollment target places it among the larger protocols in the corpus, above the 1,129-participant average among 176 other Malignant Solid Neoplasm trials with a reported enrollment target (83% higher).
The record links to 1 condition, with Malignant Solid Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Biospecimen Collection is the first listed.
NCT04871542 lists 6 locations in 1 state (Iowa).
Frequently Asked Questions
What is clinical trial NCT04871542 about?
NCT04871542 is a clinical study titled "Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors". This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is th...
What is the current status of trial NCT04871542?
This trial is currently recruiting. The enrollment target is 2,062 participants. The study started on 2021-09-13. Estimated completion is 2028-03-14.
What conditions does trial NCT04871542 study?
This clinical trial studies the following conditions: Malignant Solid Neoplasm.
What interventions are being tested in trial NCT04871542?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Questionnaire Administration (OTHER).
Who is sponsoring clinical trial NCT04871542?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04871542 being conducted?
This trial has 6 study locations across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Malignant Solid Neoplasm
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04871542's enrollment target sits among peer trials
2,062 13th of 176 higher than 164 of 176 other Malignant Solid Neoplasm trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Malignant Solid Neoplasm trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy
RECRUITING
-
Investigating Memory and Physical Activity After Cancer Treatment in Survivors of Adolescent and Young Adult Cancers
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
RECRUITING · NA
-
Voices: Messages of Wisdom and Hope in the Face of Illness
RECRUITING
-
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06521944 · 2,062 participants
RSV Vaccine Pregnancy Registry
- NCT07168993 · 2,063 participants · NA
Evaluate the Clinical Performance of the Flow Cytometry - FlowPath Lung Test as a Sensitive and Specific Non-invasive Diagnostic of Sputum Samples to Identify/Detect the Presence of Lung Cancer in High-risk Individuals Who Have Existing Lung Nodules, 6 to <30 mm in Diameter, Determined by LDCT.
- NCT06666192 · 2,067 participants · NA
The Ohio State University (OSU) SCREEN Community Program
- NCT00588068 · 2,070 participants
Molecular Characterization of Neuroblastic Tumor: Correlation With Clinical Outcome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI